^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    AMG 553

    i
    Other names: AMG 553, AMG-553
    Associations

    News

    Trials
    Company:
    Amgen
    Drug class:
    FLT3-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    over2years
    Study Evaluating the Safety, Tolerability, and Efficacy of FLT3 CAR-T AMG 553 in FLT3-positive Relapsed/Refractory AML (clinicaltrials.gov)
    P1, N=0, Withdrawn, Amgen | N=40 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal • CAR T-Cell Therapy
    |
    AMG 553
    over5years
    Nonclinical Safety Assessment of AMG 553, an Investigational Chimeric Antigen Receptor (CAR) T-cell Therapy for the Treatment of Acute Myeloid Leukemia. (PubMed, Toxicol Sci)
    Potential AMG 553-induced cytotoxicity was assessed against a wide range of normal human primary cells and cell lines; cytotoxicity was observed against FLT3-positive AML cell lines and a percentage of primary bone marrow CD34+ cells. In conclusion, the nonclinical safety data suggest that AMG 553 can target FLT3 protein on AML cells while only affecting a percentage of normal hematopoietic stem and progenitor cells, supporting clinical development.
    Clinical • Journal
    |
    FLT3 (Fms-related tyrosine kinase 3) • CD34 (CD34 molecule)
    |
    AMG 553